Notice: This company has been marked as potentially delisted and may not be actively trading. Graf Acquisition Corp IV (GFOR) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends GFOR vs. FNCH, CGTX, CYTH, NKGN, AIM, CERO, PMCB, TSBX, APTO, and BCDAShould you be buying Graf Acquisition Corp IV stock or one of its competitors? The main competitors of Graf Acquisition Corp IV include Finch Therapeutics Group (FNCH), Cognition Therapeutics (CGTX), Cyclo Therapeutics (CYTH), NKGen Biotech (NKGN), AIM ImmunoTech (AIM), CERo Therapeutics (CERO), PharmaCyte Biotech (PMCB), Turnstone Biologics (TSBX), Aptose Biosciences (APTO), and BioCardia (BCDA). These companies are all part of the "biological products, except diagnostic" industry. Graf Acquisition Corp IV vs. Finch Therapeutics Group Cognition Therapeutics Cyclo Therapeutics NKGen Biotech AIM ImmunoTech CERo Therapeutics PharmaCyte Biotech Turnstone Biologics Aptose Biosciences BioCardia Graf Acquisition Corp IV (NYSE:GFOR) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, community ranking, earnings, analyst recommendations and dividends. Does the MarketBeat Community prefer GFOR or FNCH? Finch Therapeutics Group received 10 more outperform votes than Graf Acquisition Corp IV when rated by MarketBeat users. CompanyUnderperformOutperformGraf Acquisition Corp IVN/AN/AFinch Therapeutics GroupOutperform Votes1052.63% Underperform Votes947.37% Do institutionals and insiders have more ownership in GFOR or FNCH? 28.5% of Graf Acquisition Corp IV shares are owned by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are owned by institutional investors. 20.0% of Graf Acquisition Corp IV shares are owned by insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is GFOR or FNCH more profitable? Graf Acquisition Corp IV's return on equity of -2.50% beat Finch Therapeutics Group's return on equity.Company Net Margins Return on Equity Return on Assets Graf Acquisition Corp IVN/A -2.50% 0.09% Finch Therapeutics Group N/A -69.14%-26.92% Does the media refer more to GFOR or FNCH? In the previous week, Finch Therapeutics Group had 1 more articles in the media than Graf Acquisition Corp IV. MarketBeat recorded 1 mentions for Finch Therapeutics Group and 0 mentions for Graf Acquisition Corp IV. Graf Acquisition Corp IV's average media sentiment score of 0.00 equaled Finch Therapeutics Group'saverage media sentiment score. Company Overall Sentiment Graf Acquisition Corp IV Neutral Finch Therapeutics Group Neutral Which has more risk & volatility, GFOR or FNCH? Graf Acquisition Corp IV has a beta of 0.17, suggesting that its share price is 83% less volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Which has better earnings & valuation, GFOR or FNCH? Graf Acquisition Corp IV has higher earnings, but lower revenue than Finch Therapeutics Group. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGraf Acquisition Corp IVN/AN/A$4.55MN/AN/AFinch Therapeutics Group$110K160.60-$74.75M-$8.82-1.25 SummaryFinch Therapeutics Group beats Graf Acquisition Corp IV on 5 of the 9 factors compared between the two stocks. Ad Behind the Markets⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Click here for the ticker >>> Get Graf Acquisition Corp IV News Delivered to You Automatically Sign up to receive the latest news and ratings for GFOR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GFOR vs. The Competition Export to ExcelMetricGraf Acquisition Corp IVBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$6.64M$2.94B$5.14B$19.18BDividend YieldN/A1.90%5.09%3.63%P/E RatioN/A46.7390.0541.26Price / SalesN/A415.011,116.2517.51Price / Cash39.15182.1043.1021.28Price / Book-3.373.894.785.32Net Income$4.55M-$42.21M$120.31M$989.88M Graf Acquisition Corp IV Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GFORGraf Acquisition Corp IVN/A$0.64+13.3%N/A-78.2%$6.64MN/A0.002,021Gap UpFNCHFinch Therapeutics GroupN/A$11.74-0.5%N/A+251.4%$18.85M$110,000.00-1.34190News CoverageCGTXCognition Therapeutics2.9058 of 5 stars$0.43-4.4%$8.00+1,745.4%-62.9%$18.01MN/A-0.4520Analyst ForecastNews CoverageCYTHCyclo Therapeutics3.2028 of 5 stars$0.62flat$0.95+53.5%-65.2%$17.81M$870,725.00-0.699News CoverageNKGNNKGen BiotechN/A$0.49-4.9%N/A-77.4%$17.46M$80,000.00-0.10N/AGap UpAIMAIM ImmunoTech2.3673 of 5 stars$0.22flat$2.75+1,161.5%-60.4%$13.90M$190,000.00-0.4820CEROCERo TherapeuticsN/A$0.09-18.2%N/AN/A$13.47MN/A0.008PMCBPharmaCyte Biotech0.4266 of 5 stars$1.62-3.0%N/A-24.8%$12.44MN/A2.532Earnings ReportTSBXTurnstone Biologics2.8506 of 5 stars$0.51+2.0%$2.13+316.7%-80.2%$11.56M$19.31M-0.1682Positive NewsGap DownAPTOAptose Biosciences2.6342 of 5 stars$0.19-5.0%$4.33+2,189.1%-87.7%$11.27MN/A-0.0631News CoverageGap UpBCDABioCardia3.3081 of 5 stars$2.27-2.6%$25.00+1,001.3%-79.8%$10.41M$71,000.00-0.5616Analyst ForecastShort Interest ↓Positive NewsGap Up Related Companies and Tools Related Companies FNCH Alternatives CGTX Alternatives CYTH Alternatives NKGN Alternatives AIM Alternatives CERO Alternatives PMCB Alternatives TSBX Alternatives APTO Alternatives BCDA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:GFOR) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Graf Acquisition Corp IV Please log in to your account or sign up in order to add this asset to your watchlist. Share Graf Acquisition Corp IV With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GFOR Stock Alerts